|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-11-20
|
|
pubmed:abstractText |
As new therapeutic options for multiple myeloma (MM) emerge, identification of biological markers which could predict clinical response to standard treatment with high-dose melphalan (HDM) supported by autologous stem cell transplantation (ASCT) becomes more important.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1505-12
|
|
pubmed:meshHeading |
pubmed-meshheading:18024399-Adult,
pubmed-meshheading:18024399-Aged,
pubmed-meshheading:18024399-DNA Damage,
pubmed-meshheading:18024399-Female,
pubmed-meshheading:18024399-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:18024399-Humans,
pubmed-meshheading:18024399-Male,
pubmed-meshheading:18024399-Melphalan,
pubmed-meshheading:18024399-Middle Aged,
pubmed-meshheading:18024399-Multiple Myeloma,
pubmed-meshheading:18024399-Patient Selection,
pubmed-meshheading:18024399-Predictive Value of Tests,
pubmed-meshheading:18024399-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.
|
|
pubmed:affiliation |
Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece. mdimop@med.uoa.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
